Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short-term Investments (2022 - 2026)

Summit Therapeutics filings provide 5 years of Short-term Investments readings, the most recent being $316000.0 for Q1 2026.

  • Quarterly Short-term Investments fell 0.63% to $316000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $316000.0 through Mar 2026, down 0.63% year-over-year, with the annual reading at $316000.0 for FY2025, 99.9% down from the prior year.
  • Short-term Investments hit $316000.0 in Q1 2026 for Summit Therapeutics, roughly flat from $316000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $307.5 million in Q4 2024 and bottomed at $316000.0 in Q4 2025.
  • Average Short-term Investments over 5 years is $86.7 million, with a median of $321000.0 recorded in 2025.
  • Peak annual rise in Short-term Investments hit 0.32% in 2025, while the deepest fall reached 99.9% in 2025.
  • Summit Therapeutics' Short-term Investments stood at $300.0 million in 2022, then crashed by 42.37% to $172.9 million in 2023, then soared by 77.84% to $307.5 million in 2024, then tumbled by 99.9% to $316000.0 in 2025, then changed by 0.0% to $316000.0 in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Short-term Investments are $316000.0 (Q1 2026), $316000.0 (Q4 2025), and $321000.0 (Q3 2025).